| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
AJP - Gastrointestinal and Liver Physiology, Vol 272, Issue 3 662-G668, Copyright © 1997 by American Physiological Society
ARTICLES |
C. H. Tsai, M. Hill and D. J. Drucker
Department of Medicine, University of Toronto, Ontario, Canada.
Glucagon-like peptide 2 (GLP-2) appears to regulate growth of the small bowel epithelium. The importance of dose, vehicle, and route of administration for GLP-2 bioactivity was examined in vivo. Mouse small bowel weight increased following subcutaneous injection of GLP-2, 0.25 to 5.0 microg twice daily, with an increment in jejunal crypt plus villus height detected with only 250 ng GLP-2 twice daily for 14 days (1.35-fold greater than control, P < 0.05). Small bowel weight was increased by 6 days of GLP-2 administration (1.4-fold greater than control, P < 0.05) and further increased after up to 14 days of GLP-2 treatment (P < 0.001, GLP-2 vs. control). GLP-2 increased small bowel weight in either 12% gelatin or phosphate-buffered saline (PBS) formulations (P < 0.01 vs. P < 0.05, gelatin vs. PBS, respectively), and GLP-2 was intestinotrophic following either intramuscular, intraperitoneal, or subcutaneous administration (P < 0.05 for im and ip, P < 0.001 for sc, GLP-2 vs. control). GLP-2 also induced bowel growth when administered daily or every other day. These results define important biological parameters for the activity of GLP-2 in vivo.
This article has been cited by other articles:
|
|
 |
|
  A. Ramsanahie, M. S. Duxbury, T. C. Grikscheit, A. Perez, D. B. Rhoads, J. Gardner-Thorpe, J. Ogilvie, S. W. Ashley, J. P. Vacanti, and E. E. Whang Effect of GLP-2 on mucosal morphology and SGLT1 expression in tissue-engineered neointestine Am J Physiol Gastrointest Liver Physiol, December 1, 2003; 285(6): G1345 - G1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Gillingham, E. M. Dahly, S. G. Murali, and D. M. Ney IGF-I treatment facilitates transition from parenteral to enteral nutrition in rats with short bowel syndrome Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R363 - R371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Drucker Gut adaptation and the glucagon-like peptides Gut, March 1, 2002; 50(3): 428 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P B Jeppesen, B Hartmann, J Thulesen, B S Hansen, J J Holst, S S Poulsen, and P B Mortensen Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon Gut, September 1, 2000; 47(3): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M A Benjamin, D M McKay, P-C Yang, H Cameron, and M H Perdue Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse Gut, July 1, 2000; 47(1): 112 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Thulesen, B Hartmann, C Nielsen, J J Holst, and S S Poulsen Diabetic intestinal growth adaptation and glucagon-like peptide 2 in the rat: effects of dietary fibre Gut, November 1, 1999; 45(5): 672 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Munroe, A. K. Gupta, F. Kooshesh, T. B. Vyas, G. Rizkalla, H. Wang, L. Demchyshyn, Z.-J. Yang, R. K. Kamboj, H. Chen, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2 PNAS, February 16, 1999; 96(4): 1569 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Drucker, B. Yusta, R. P. Boushey, L. DeForest, and P. L. Brubaker Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis Am J Physiol Gastrointest Liver Physiol, January 1, 1999; 276(1): G79 - G91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Scott, D. Kirk, W. K. MacNaughton, and J. B. Meddings GLP-2 augments the adaptive response to massive intestinal resection in rat Am J Physiol Gastrointest Liver Physiol, November 1, 1998; 275(5): G911 - G921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Drucker, L. Deforest, and P. L. Brubaker Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2 Am J Physiol Gastrointest Liver Physiol, December 1, 1997; 273(6): G1252 - G1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Fischer, S. Dhanvantari, D. J. Drucker, and P. L. Brubaker Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats Am J Physiol Endocrinol Metab, October 1, 1997; 273(4): E815 - E820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lovshin, J. Estall, B. Yusta, T. J. Brown, and D. J. Drucker Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling J. Biol. Chem., June 8, 2001; 276(24): 21489 - 21499. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
